Difference between revisions of "Pidilizumab (CT-011)"
Jump to navigation
Jump to search
(Created page with "==Diseases for which it is used== *Aggressive Non-Hodgkin lymphoma") |
|||
| Line 1: | Line 1: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Aggressive Non-Hodgkin lymphoma]] | *[[Aggressive Non-Hodgkin lymphoma]] | ||
| + | *[[Follicular lymphoma]] | ||
| + | |||
| + | ==Pre-approval references== | ||
| + | # Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70551-5/fulltext?elsca1=ETOC-ONCOLOGY&elsca2=email&elsca3=P24A35F link to original article] Epub 2013 Dec 11. [http://www.ncbi.nlm.nih.gov/pubmed/24332512 PubMed] | ||
Revision as of 15:42, 6 January 2014
Diseases for which it is used
Pre-approval references
- Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. link to original article Epub 2013 Dec 11. PubMed